These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 29114967)
21. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. French LE; Trent JT; Kerdel FA Int Immunopharmacol; 2006 Apr; 6(4):543-9. PubMed ID: 16504917 [TBL] [Abstract][Full Text] [Related]
22. Intravenous immunoglobulin increases plasma viscosity without parallel rise in blood pressure. Bentley P; Rosso M; Sadnicka A; Israeli-Korn S; Laffan M; Sharma P J Clin Pharm Ther; 2012 Jun; 37(3):286-90. PubMed ID: 21767284 [TBL] [Abstract][Full Text] [Related]
26. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders. Markvardsen LH; Christiansen I; Harbo T; Jakobsen J Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709 [TBL] [Abstract][Full Text] [Related]
27. Intravenous immunoglobulin and the kidney--a two-edged sword. Orbach H; Tishler M; Shoenfeld Y Semin Arthritis Rheum; 2004 Dec; 34(3):593-601. PubMed ID: 15609263 [TBL] [Abstract][Full Text] [Related]
28. European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. Enk AH; Hadaschik EN; Eming R; Fierlbeck G; French LE; Girolomoni G; Hertl M; Jolles S; Karpati S; Steinbrink K; Stingl G; Volc-Platzer B; Zillikens D J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1657-1669. PubMed ID: 27406069 [TBL] [Abstract][Full Text] [Related]
29. Anti-SSA antibodies are present in immunoglobulin preparations. van der Molen RG; Hamann D; Jacobs JF; van der Meer A; de Jong J; Kramer C; Strengers PF; van der Meer JW Transfusion; 2015 Apr; 55(4):832-7. PubMed ID: 25394209 [TBL] [Abstract][Full Text] [Related]
30. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Prins C; Vittorio C; Padilla RS; Hunziker T; Itin P; Förster J; Bröcker EB; Saurat JH; French LE Dermatology; 2003; 207(1):96-9. PubMed ID: 12835566 [TBL] [Abstract][Full Text] [Related]
31. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis. Khalili B; Bahna SL Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130 [TBL] [Abstract][Full Text] [Related]
32. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. Kirchhof MG; Miliszewski MA; Sikora S; Papp A; Dutz JP J Am Acad Dermatol; 2014 Nov; 71(5):941-7. PubMed ID: 25087214 [TBL] [Abstract][Full Text] [Related]
33. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. Morici MV; Galen WK; Shetty AK; Lebouef RP; Gouri TP; Cowan GS; Gedalia A J Rheumatol; 2000 Oct; 27(10):2494-7. PubMed ID: 11036849 [TBL] [Abstract][Full Text] [Related]
34. Intravenous immunoglobulin-induced haemolysis: a case report and review of the literature. Desborough MJ; Miller J; Thorpe SJ; Murphy MF; Misbah SA Transfus Med; 2014 Aug; 24(4):219-26. PubMed ID: 24164446 [TBL] [Abstract][Full Text] [Related]
35. IVIG for the treatment of toxic epidermal necrolysis. Mittmann N; Chan BC; Knowles S; Shear NH Skin Therapy Lett; 2007 Feb; 12(1):7-9. PubMed ID: 17361314 [TBL] [Abstract][Full Text] [Related]
36. Neutropenia as a complication of high-dose intravenous immunoglobulin therapy in adult patients with neuroimmunologic disorders. Matsuda M; Hosoda W; Sekijima Y; Hoshi K; Hashimoto T; Itoh S; Ikeda S Clin Neuropharmacol; 2003; 26(6):306-11. PubMed ID: 14646610 [TBL] [Abstract][Full Text] [Related]